← GYRE THERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $1.0m |
$6k
-99.41%
|
$2.1m
+35650.00%
|
$20.9m
+876.60%
|
$7.3m
-64.97%
|
$794k
-89.18%
|
$113.5m
+14188.41%
|
$105.8m
-6.78%
|
$116.6m
+10.24%
|
$109.8m
-5.81%
|
|
| Cost of Revenue | $11.2m |
$12.8m
+15.16%
|
$21.5m
+67.15%
|
$46.0m
+114.23%
|
$9.2m
-80.08%
|
$7.4m
-19.46%
|
$798k
-89.19%
|
$4.6m
+480.95%
|
$3.9m
-16.22%
|
$5.4m
+39.44%
|
$6.8m
+25.68%
|
|
| Gross Profit (derived) | ($11.2m) |
($11.8m)
-6.03%
|
($21.5m)
-81.49%
|
($43.9m)
-104.30%
|
$11.8m
+126.87%
|
($42k)
-100.36%
|
($4k)
+90.48%
|
$108.8m
+2720450.00%
|
$101.9m
-6.38%
|
$111.2m
+9.13%
|
$103.0m
-7.34%
|
|
| Interest Income (Expense), Net | — | — | — | — | — | — | — | $1.0m |
$1.5m
+48.18%
|
$1.7m
+12.93%
|
$1.4m
-17.97%
|
|
| Research and Development Expense | $11.6m | $12.8m | $21.5m | $43.9m | $53.0m | $68.9m | $13.0m | $13.8m | $12.0m | $13.7m | $27.9m | |
| Selling and Marketing Expense | — | — | — | — | — | — | $54.2m | $61.2m | $57.5m | $65.2m | $90.4m | |
| General and Administrative Expense | $9.3m | $10.0m | $12.4m | $13.4m | $16.2m | $19.0m | $17.4m | $14.7m | $16.1m | $20.8m | $23.4m | |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | $100k | $38k | $576k | — | |
| Operating Lease, Expense | — | — | — | $600k | $700k | $1.7m | $1.7m | $500k | $700k | $900k | — | |
| Operating Expenses | $20.8m | $22.8m | $33.8m | $57.3m | $78.3m | $95.2m | $9.4m | $176.0m | $85.7m | $105.1m | $118.3m | |
| Total operating expenses | $20.8m | $22.8m | $33.8m | $57.3m | $78.3m | $95.2m | $9.4m | $180.7m | $89.6m | $105.1m | $118.3m | |
| Operating Income (Loss) | ($20.4m) |
($21.8m)
-6.88%
|
($33.8m)
-54.99%
|
($57.3m)
-69.35%
|
($57.4m)
-0.16%
|
($87.9m)
-53.21%
|
($8.6m)
+90.20%
|
($67.2m)
-680.75%
|
$16.2m
+124.04%
|
$11.5m
-28.93%
|
($15.3m)
-232.86%
|
|
| Interest income, net | — | — | — | — | — | — | $726k | $1.0m | $1.5m | $1.7m | $1.4m | |
| Other Nonoperating Income (Expense) | $86k | $261k | $1.6m | ($39k) | $659k | ($87k) | — | — | ($1.7m) | ($1.5m) | — | |
| Other expense, net | — | — | — | — | — | — | — | ($1.5m) | ($1.7m) | ($1.5m) | — | |
| Interest Income (Expense), Nonoperating, Net | — | — | $2.2m | $2.1m | $561k | $39k | $537k | — | — | — | $1.4m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | — | ($5.2m) | ($22.3m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | ($87.9m) | ($7.9m) | ($77.0m) | $23.2m | $14.4m | ($22.3m) | |
| Provision for income taxes | — | — | — | — | — | — | $348k | ($8.5m) | ($5.3m) | ($4.6m) | — | |
| Current Income Tax Expense (Benefit) | — | — | — | — | — | — | — | $9.3m | $6.3m | $5.7m | $3.4m | |
| Net Income (Loss) Attributable to Parent | ($16.9m) |
($21.6m)
-27.24%
|
($30.1m)
-39.40%
|
($55.2m)
-83.59%
|
($56.2m)
-1.93%
|
($87.9m)
-56.35%
|
($8.2m)
+90.63%
|
($85.5m)
-937.13%
|
$17.9m
+120.94%
|
$9.9m
-44.80%
|
($19.9m)
-301.50%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | — | ($25.5m) |
($30.1m)
-17.81%
|
($55.2m)
-83.59%
|
($56.2m)
-1.93%
|
— | $4.3m |
($92.9m)
-2254.22%
|
$12.1m
+113.00%
|
$5.0m
-58.40%
|
($19.9m)
-496.02%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | — | — | $2.0m | $7.5m | $5.8m | $4.9m | ($19.9m) | |
| Preferred Stock Dividends, Income Statement Impact | — | $4 | — | — | — | — | — | — | — | — | — | |
| Earnings Per Share, Basic | — | — | — | — | — | — | ($0.26) | ($1.41) | $0.14 | $0.06 | ($0.20) | |
| Earnings Per Share, Diluted | ($21.75) | — | — | — | — | — | ($0.26) | ($1.41) | $0.05 | $0.02 | ($0.21) | |
| Common Stock, Dividends, Per Share, Declared | — | — | — | — | — | — | $0.24 | — | — | — | — | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | — | 31.5m | 65.8m | 85.1m | 89.3m | 93.7m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | — | 31.5m | 65.8m | 102.3m | 103.2m | 107.5m | |
| Additional Financial Items | ||||||||||||
| Comprehensive income from operations | — | — | — | — | — | — | ($614k) | ($87.0m) | $16.4m | $12.5m | — | |
| Costs and Expenses | — | — | — | — | — | — | — | $180.7m | $89.6m | $105.1m | — | |
| Loss on disposal of assets, net | — | — | — | — | — | — | ($57.2m) | — | $66k | $4k | — | |
| Change in fair value of warrant liability | — | — | — | — | — | — | — | ($9.3m) | $7.2m | $2.7m | — | |
| Foreign currency translation adjustments | — | — | — | — | — | — | ($4.9m) | ($1.5m) | ($1.5m) | $2.6m | — | |
| Foreign currency translation adjustments attributable to noncontrolling interest | — | — | — | — | — | — | ($2.2m) | ($647k) | ($507k) | $818k | — | |
| Comprehensive income attributable to noncontrolling interest | — | — | — | — | — | — | ($158k) | $6.8m | $5.3m | $5.7m | — | |
| Comprehensive income attributable to common stockholders | — | — | — | — | — | — | ($456k) | ($93.8m) | $11.1m | $6.8m | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | $2.0m | ($85.5m) | $17.9m | $9.9m | — |